or
forgot password

Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Hodgkin's Lymphoma, Multiple Myeloma, Non-Hodgkin's Lymphoma

Thank you

Trial Information

Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant


Inclusion Criteria:



- Patients receiving an autologous stem cell transplant using the preparative regimens
of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or
Melphalan 200mg/m2

- Any prior diet or supplement will be allowed.

- Age >18 years.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Nestle Impact including fish oil.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Hospital length of stay

Outcome Time Frame:

Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge

Safety Issue:

No

Principal Investigator

John W Hayslip, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Lucille P. Markey Cancer Center at University of Kentucky

Authority:

United States: Food and Drug Administration

Study ID:

11-HEM-03-MCC

NCT ID:

NCT01699581

Start Date:

September 2012

Completion Date:

October 2015

Related Keywords:

  • Hodgkin's Lymphoma
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Hodgkin's Lymphoma
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location
University of Kentucky, Markey Cancer Center Lexington, Kentucky  40536-0093